CLINICAL TRIALS PROFILE FOR MODAFINIL
✉ Email this page to a colleague
505(b)(2) Clinical Trials for MODAFINIL
Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|---|
New Combination | NCT03182413 ↗ | Impact of THN102 on Attention, Wakefulness and Cognitive Performance During Total Sleep Deprivation | Completed | Institut de recherche biomédicale des armées (IRBA), Bretigny sur Orge, France | Phase 1 | 2015-09-01 | Study Objectives: THN102 is a new combination between modafinil and flecainide low-dose, a documented glial connexin inhibitor. Efficacy of THN102 was compared to modafinil and to placebo on parameters impaired by total sleep deprivation (SD, lasting 40h). Methods: 20 healthy male subjects participated in a double-blind, randomised, incomplete-block 3-period cross-over trial involving 5 treatments (n=12 per group): placebo (PBO), modafinil 100 mg (MOD), and combinations THN102 (modafinil 100 mg and 1, 3 or 9 mg flecainide as THN1, THN3 and THN9), as 3 oral doses over 18h. |
New Combination | NCT03182413 ↗ | Impact of THN102 on Attention, Wakefulness and Cognitive Performance During Total Sleep Deprivation | Completed | Theranexus | Phase 1 | 2015-09-01 | Study Objectives: THN102 is a new combination between modafinil and flecainide low-dose, a documented glial connexin inhibitor. Efficacy of THN102 was compared to modafinil and to placebo on parameters impaired by total sleep deprivation (SD, lasting 40h). Methods: 20 healthy male subjects participated in a double-blind, randomised, incomplete-block 3-period cross-over trial involving 5 treatments (n=12 per group): placebo (PBO), modafinil 100 mg (MOD), and combinations THN102 (modafinil 100 mg and 1, 3 or 9 mg flecainide as THN1, THN3 and THN9), as 3 oral doses over 18h. |
>Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for MODAFINIL
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00033046 ↗ | Evaluation of Modafinil as a Cocaine Treatment Medication and Interactions With Cocaine - 1 | Unknown status | National Institute on Drug Abuse (NIDA) | Phase 1 | 2001-06-01 | The purpose of this study is to evaluate modafinil, a cocaine treatment medication, and its interactions with intravenous (IV) cocaine. |
NCT00042848 ↗ | Modafinil in Treating Fatigue in Patients Receiving Chemotherapy for Cancer | Completed | National Cancer Institute (NCI) | Phase 3 | 2002-08-01 | RATIONALE: Modafinil may be effective in relieving fatigue in patients with cancer who are undergoing chemotherapy. The effectiveness of modafinil in relieving chemotherapy-related fatigue is not yet known. PURPOSE: This randomized phase III trial is studying the effectiveness of modafinil in treating fatigue in patients who are receiving chemotherapy for cancer. |
NCT00042848 ↗ | Modafinil in Treating Fatigue in Patients Receiving Chemotherapy for Cancer | Completed | Gary Morrow | Phase 3 | 2002-08-01 | RATIONALE: Modafinil may be effective in relieving fatigue in patients with cancer who are undergoing chemotherapy. The effectiveness of modafinil in relieving chemotherapy-related fatigue is not yet known. PURPOSE: This randomized phase III trial is studying the effectiveness of modafinil in treating fatigue in patients who are receiving chemotherapy for cancer. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MODAFINIL
Condition Name
Clinical Trial Locations for MODAFINIL
Trials by Country
Clinical Trial Progress for MODAFINIL
Clinical Trial Phase
Clinical Trial Sponsors for MODAFINIL
Sponsor Name